Document Detail


Growth hormone deficiency and vascular risk.
MedLine Citation:
PMID:  12100064     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The importance of growth hormone deficiency (GHD) in adult life has become more apparent over the last decade. As well as a distinct clinical syndrome there is a significant excess risk of cardiovascular disease. Although it is difficult to ascertain what part is played by the original pituitary disorder and the concomitant replacement hormonal therapies, there is clear evidence that GHD is associated with known cardiovascular risk factors such as body shape, lipid profile, insulin resistance, blood pressure, vessel wall morphology and haemostatic factors. Novel means of assessing vascular risk such as pulse wave velocity and flow-mediated dilatation can also estimate the risk without invasive procedures. The role of possible mediators of endothelial function such as nitric oxide and free radicals is being investigated further. Replacement of GH in GH-deficient patients leads to many effects on the above indices, some but not all of which are associated with reduced vascular risk. Long-term follow-up studies of morbidity and mortality are required for an accurate assessment of the beneficial effects of therapy.
Authors:
Roland W McCallum; John R Petrie; Anna F Dominiczak; John M C Connell
Related Documents :
8520274 - Utilisation of hormone replacement therapy by women doctors.
14644824 - Miniature, low-dose, intrauterine drug-delivery systems.
12466764 - Young hiv-infected adults are at greater risk for medication nonadherence.
10999494 - Myocardial infarction in women: a critical appraisal of gender differences in outcomes.
15641864 - A preliminary study of risperidone in the treatment of posttraumatic stress disorder re...
9729584 - Energy requirements and physical activity in free-living older women and men: a doubly ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical endocrinology     Volume:  57     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-07-08     Completed Date:  2002-09-10     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  11-24     Citation Subset:  IM    
Affiliation:
Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK. roland.mccallum@ntlworld.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cardiovascular Diseases / etiology*,  prevention & control
Endothelium, Vascular / physiopathology
Great Britain
Hemostasis
Human Growth Hormone / therapeutic use
Humans
Hypertension / complications
Pituitary Diseases / complications*,  drug therapy,  epidemiology
Prevalence
Risk
Somatostatin / deficiency*
Vascular Resistance
Chemical
Reg. No./Substance:
12629-01-5/Human Growth Hormone; 51110-01-1/Somatostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance.
Next Document:  Serum leptin concentrations of patients with sequential thyroid function changes.